STUB1 and therapy-related myeloid neoplasm: Clinical trials of lenalidomide with or without daratumumab for post-HSCT maintenance therapy are ongoing (AURIGA-NCT03901963 and S1803-NCT04071457), which may shed light on the impact of daratumuamb on CHIP and subsequent development of TMN.